Table 2.
Immunohistochemical staining results of ER/PR/HER2, CK5/6, and EGFR
| |
|
ER |
|
|
PR |
|
|
HER2 |
|
|
CK5 |
|
|
EGFR |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case | Intensity | Location | Percent | Intensity | Location | Percent | Intensity | Location | Percent | Intensity | Location | Percent | Intensity | Location | Percent |
| 1 |
|
|
0 |
1 |
N* |
5 |
|
|
0 |
3 |
M, C* |
100 |
|
|
0 |
|
2 |
|
|
0 |
|
|
0 |
|
|
0 |
3 |
M, C |
100 |
|
|
0 |
| 3 |
|
|
0 |
|
|
0 |
2 |
C, M |
20 |
3 |
M |
20 |
2 |
C, M |
80 |
| 4 |
1 |
N |
40 |
|
|
0 |
2 |
M |
20 |
3 |
M |
100 |
2 |
M |
15 |
| 5 |
1 |
N |
10 |
|
|
0 |
|
|
0 |
3 |
M |
30 |
2 |
M |
50 |
|
6 |
|
|
0 |
|
|
0 |
|
|
0 |
3 |
C, M |
40 |
1 |
M |
5 |
|
7 |
|
|
0 |
|
|
0 |
|
|
0 |
3 |
M, C |
80 |
1 |
M |
60 |
| 8 |
|
|
0 |
|
|
0 |
|
|
0 |
|
|
0 |
|
|
0 |
|
9 |
|
|
0 |
|
|
0 |
|
|
0 |
3 |
C, M |
25 |
1 |
C, M |
30 |
| 10 |
|
|
0 |
1 |
N |
5 |
|
|
0 |
3 |
C, M |
5 |
1 |
C |
10 |
| 11 |
|
|
0 |
3 |
N |
90 |
|
|
0 |
|
|
0 |
|
|
0 |
| 12 |
|
|
0 |
2 |
N |
80 |
|
|
0 |
|
|
0 |
1 |
M |
5 |
| 13 |
|
|
0 |
1 |
N |
10 |
2 |
C, M |
40 |
3 |
M |
80 |
1 |
M, C |
15 |
|
14 |
|
|
0 |
|
|
0 |
|
|
0 |
3 |
M |
100 |
|
|
0 |
|
15 |
|
|
0 |
|
|
0 |
|
|
0 |
3 |
M, C |
70 |
1 |
C, M |
30 |
| 16 |
|
|
0 |
1 |
N |
30 |
|
|
0 |
3 |
M |
50 |
2 |
C, M |
50 |
|
17 |
|
|
0 |
|
|
0 |
|
|
0 |
|
|
0 |
2 |
M, C |
30 |
| 18 |
|
|
0 |
|
|
0 |
|
|
0 |
|
|
0 |
|
|
0 |
|
19 |
|
|
0 |
|
|
0 |
|
|
0 |
3 |
M, C |
90 |
2 |
M |
90 |
|
20 |
|
|
0 |
|
|
0 |
|
|
0 |
3 |
M |
90 |
1 |
M |
80 |
| 21 |
|
|
0 |
1 |
N |
5 |
2 |
M |
30 |
|
|
0 |
|
|
0 |
|
22 |
|
|
0 |
|
|
0 |
|
|
0 |
3 |
M |
20 |
1 |
C, M |
70 |
| 23 |
|
|
0 |
|
|
0 |
|
|
0 |
|
|
0 |
|
|
0 |
| 24 | 0 | 0 | 0 | 3 | M | 70 | 0 |
*N nuclear, C cytoplasmic, M membranous.
Feline triple-negative, basal-like adenocarcinomas (case numbers 2, 6, 7, 9, 14, 15, 17, 19, 20, 22, 24 in italicized boldface) were submitted for genetic analysis.